Press Releases | Zevra Therapeutics, Inc. - Investor Relations
investors.kempharm.com › news-releases
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual ...
The Investor Relations website contains information about Zevra Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
KemPharm's common stock will be listed on The Nasdaq Capital Market and will trade under the ticker symbol “KMPH” beginning today, January 8, 2021 . The ...
Past Events ; 23rd Annual Needham Virtual Healthcare Conference. 04-08-2024 3:45 PM EDT ; Zevra Therapeutics Q4 2023 Earnings Call. 03-28-2024 4:30 PM EDT ; 36th ...
Missing: kmph | Show results with:kmph
Jun 24, 2022 · Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects.
Missing: relations | Show results with:relations
Ochsner served as Executive Vice President of Investor Relations and Corporate Communications with Statera Biopharma. ... Stock KMPH logo. Zevra Therapeutics Inc ...
Nov 9, 2022 · I will now turn the call over to Nichol Ochsner, KemPharm's Vice President, Investor Relations and Corporate Communications. Thank you. Ma ...
Below are the latest news stories about KEMPHARM INC that investors may wish to consider to help them evaluate KMPH as an investment opportunity. Zevra ...
The audio webcast with a slide presentation will be accessible via the Investor Relations section of t. GlobeNewswire•11 months ago. KMPH · Zevra Therapeutics ...
$3.52
KMPH stocks based on their intrinsic value. ... VP of Investor Relations & Corp. Communications ... Most Undervalued Stocks High Profitability Stocks High Solvency ...